口服葡萄糖耐量试验峰值血糖与囊性纤维化成人未来糖尿病风险相关
基于蒙特利尔囊性纤维化队列的横断面(n=293)与前瞻性观察(n=185,平均随访7.5±4.2年)分析,研究2小时OGTT每30分钟采样的指标与肺功能、BMI及囊性纤维化相关糖尿病(CFRD)风险的关系。结果显示OGTT峰值血糖(Gmax)与FEV1负相关(p=0.003),与CFRD发生风险正相关(p=0.0029),Gmax<8 mmol/l者在随后十年内无一人发生CFRD。
要点
- Gmax与CFRD发生风险正相关,Gmax<8 mmol/l可识别未来CFRD极低风险者。
- Gmax与FEV1负相关(p=0.003),经典2小时血糖等其他OGTT指标未见此关联。
- Gmax较高者胰岛素分泌能力较低、胰岛素峰值延迟且胰腺外分泌功能不全更重。
核心结论
- 在囊性纤维化成人中,OGTT峰值血糖(Gmax)与未来发生CFRD的风险强烈相关。
- Gmax<8 mmol/l可识别未来CFRD风险极低的人群。
- Gmax在胰腺外分泌功能不全者中更高,并与较差的胰岛素分泌能力和肺功能相关。
研究设计与样本
- 蒙特利尔囊性纤维化队列的横断面基线分析(n=293)。
- 同一队列的观察性前瞻分析(n=185,平均随访7.5±4.2年)。
- OGTT为2小时、每30分钟采样,分析血糖与胰岛素指标同FEV1、BMI及CFRD发生风险的关系。
主要发现
- 基线时最大OGTT血糖(Gmax)与FEV1呈负相关(p=0.003),包括经典2小时血糖在内的其他OGTT值未见此关联。
- 较高的Gmax与较低的胰岛素分泌能力、胰岛素峰值时间延迟及更重的胰腺功能不全相关(p<0.01)。
- Gmax与发生CFRD的风险呈正相关(p=0.0029);Gmax<8 mmol/l者随后十年内无一人发生CFRD。
- 没有OGTT变量与BMI或FEV1的变化速率相关。
关键数值与推荐
- Gmax<8 mmol/l可识别未来CFRD极低风险者。
- Gmax与FEV1负相关(p=0.003);Gmax与CFRD发生风险正相关(p=0.0029)。
- Gmax与胰岛素分泌能力、胰岛素峰值 timing 及胰腺功能不全相关(p<0.01)。
临床怎么用
- 对囊性纤维化成人行OGTT时可关注峰值血糖(Gmax),而非仅看0和2小时血糖。
- Gmax<8 mmol/l可能提示未来CFRD风险很低,可据此调整监测强度。
- Gmax升高提示胰岛素分泌能力下降与胰腺功能不全,应结合肺功能评估。
局限性
- 基线为横断面分析,无法确立因果方向。
- 前瞻观察样本为185例,随访时间有限。
- OGTT变量与BMI、FEV1变化速率未见相关,纵向代谢影响尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Cystic fibrosis-related diabetes (CFRD) affects up to 50% of adults with cystic fibrosis (CF) and its presence is associated with adverse effects on nutritional status and pulmonary function. Early diagnosis could minimise CFRD morbidity, yet current methods of an OGTT at 0 and 2 h yield unreliable results. Our aim was to determine which indices from a 2 h OGTT with sampling every 30 min might improve prediction of CFRD. METHODS: Cross-sectional analysis at baseline (n = 293) and observational prospective analysis (n = 185; mean follow-up of 7.5 ± 4.2 years) of the Montreal Cystic Fibrosis Cohort were performed. Blood glucose and insulinaemia OGTT variables were studied in relation to lung function (forced expiratory volume in 1 s [FEV1]), BMI and risk of developing CFRD. RESULTS: At baseline, maximum OGTT glucose (Gmax) was negatively associated with FEV1 (p = 0.003). Other OGTT values, including classical 2 h glucose, were not. A higher Gmax was associated with lower insulin secretory capacity, delayed insulin peak timing and greater pancreatic insufficiency (p < 0.01). Gmax was positively associated with the risk of developing CFRD (p = 0.0029); no individual with a Gmax < 8 mmol/l developed CFRD over the following decade. No OGTT variable correlated to the rate of change in BMI or FEV1. CONCLUSIONS/INTERPRETATION: In adults with CF, Gmax is strongly associated with the risk of developing CFRD; Gmax < 8 mmol/l could identify those at very low risk of future CFRD. Gmax is higher in individuals with pancreatic insufficiency and is associated with poorer insulin secretory capacity and pulmonary function.
引用
- Bonhoure A, Potter KJ, Colomba J, et al. Peak glucose during an oral glucose tolerance test is associated with future diabetes risk in adults with cystic fibrosis. Diabetologia. 2021. PMID: 33693987. doi:10.1007/s00125-021-05423-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。